Back to Authors

Mikhail, Inas

0009-0006-4382-3586

Mayo Clinic

Mayo Clinic

Citations 3

Patients With Crohn’s Disease and Terminal Ileum Resection are at Increased Risk of Colorectal Cancer: A Population-Based Study
Mikhail, Inas , Ta’ani, Omar Al , Aburumman, Razan , Alsakarneh, Saqr, Al Ta'ani, Omar , Alsakarneh, Saqr , Farraye, Francis A. , Hashash, Jana G.

Inflammatory Bowel Diseases | June 27, 2025 | Volume: 31 | Issue: 9 | Pages: 2593-2596

10.1093/ibd/izaf118 Get It

Abstract Patients with Crohn’s disease (CD) who undergo terminal ileum (TI) resection experience altered bile acid absorption, which may influence colorectal cancer (CRC) risk. We conducted a propensity-matched cohort study using TriNetX to compare CRC risk in patients with CD who underwent TI resection versus those who did not. Terminal ileum resection was associated with an increased risk of CRC (aHR = 2.58, 95% CI, 1.72–3.86). Patients with TI resection also had higher odds of colorectal polyps. These findings suggest the need for heightened CRC surveillance in patients with CD undergoing TI resection.
Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study
Alsakarneh, Saqr , Ta’ani, Omar Al , Aburumman, Razan , Mikhail, Inas , Al Ta'ani, Omar , Alsakarneh, Saqr G , Hashash, Jana G. , Farraye, Francis A.

Alimentary Pharmacology & Therapeutics | April 7, 2025 | Volume: 62 | Issue: 1 | Pages: 72-76

10.1111/apt.70139 Get It

ABSTRACTIL‐17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL‐17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL‐17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL‐17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.
S53 Efficacy of Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 in Vaccinated Patients With Inflammatory Bowel Disease
Mikhail, Inas , Crosby, Sheena , Kochhar, Gursimran , Desai, Aakash , Hashash, Jana G. , Hayney, Mary S. , Caldera, Freddy , Farraye, Francis A.

American Journal of Gastroenterology | December 9, 2024 | Volume: 119 | Issue: 12S | Pages: S15-S15

10.14309/01.ajg.0001082744.48729.45 Get It